Screening Experts Outline Considerations for LDCT Screening Programs
Erin JungmeyerLead author Dr. Claudia Henschke says a recently published perspective from the IASLC Early Detection and Screening Committee explores several components of effective screening efforts, including timing between screenings. Read more
Research Supports Use of Lung Nodule Programs to Improve Early Detection Efforts
Erin JungmeyerA study by Dr. Raymond U. Osarogiagbon and colleagues found that such programs may benefit patients deemed too young or too old for lung cancer screening based on existing guidelines. Read more
As the IASLC celebrates its 50th year, the association’s journal moves to online only and the American Cancer Society recommends expanding screening eligibility. Read more
Risk Prediction Model Demonstrates Superior Performance vs. NELSON Criteria for Identifying Individuals for Screening
KarryAnne Belanger, PhDDr. Jens Vogel-Claussen says the PLCOm2012 model, which includes family history and other factors, detected 97% of lung cancer cases compared to a 77% detection rate with NELSON criteria. Read more
Multifaceted Approach Needed for Early Lung Cancer Detection
Matthew P. Smeltzer, PhD+more
Analyses by Drs. Matthew P. Smeltzer and Raymond U. Osarogiagbon show nodule and LDCT lung cancer screening programs may be serving two distinct populations with only moderate overlap. Read more
New Screening Approach Needed to Detect Lung Cancer in Patients who Never Smoked
Erin JungmeyerDuring ACLC 2022, Dr. Gee-Chen Chang made the case for moving beyond smoking history to identify at-risk patients and shared an alternative risk predication model that compared favorably against NLST and NELSON. Read more
Opinion: Updated Screening Guidance Needs More Commitment, Action Steps
Denis Horgan, PhD, LLM, MSc, BCLProf. Denis Horgan, executive director for the European Alliance for Personalised Medicine, writes that while the intentions behind the EU’s new cancer screening recommendations are laudable, they lack a roadmap for turning ideas into reality. Read more
Comparable Efficacy, Disruptive Price for an Alternative EGFR TKI?
H. Jack West, MD+more
Aumolertinib may ultimately prove to be an alternative to osimertinib, but it faces challenges before it can win us fda approval. Read more
Lung Cancer Risk Prediction Model Demonstrates Readiness for Clinical Application
Andrea Borondy Kitts, MS, MPHEvidence demonstrates superior performance of the PLCOm2012 model for identifying individuals for lung cancer screening. Read more
Association aims to bring attention to the often-overlooked links between air pollution and lung cancer. Read more